| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $160,655,686 ) (Continued on the next page) |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA231838 | Immunogenetics of Outcomes Disparities After Allogeneic HCT | 000 | 10 | NIH | 5/4/2026 | $438,973 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI136514 | Decoding the interactions between T cell receptors and peptide-MHC | 005 | 10 | NIH | 5/28/2026 | $860,779 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI178284 | Role of local antibodies in control of chronic genital herpes | 000 | 3 | NIH | 1/3/2026 | $865,722 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AR070780 | Differentiation balances oncogene-driven proliferation to maintain epidermal homeostasis | 000 | 10 | NIH | 6/11/2026 | $518,607 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01HL128239 | Genetic and molecular basis for SRSF2 mutations in myelodysplasia | 001 | 12 | NIH | 6/10/2026 | $764,771 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R21AI195420 | Harnessing in-tissue antibodies for therapeutic HSV control | 000 | 1 | NIH | 6/9/2026 | $238,899 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 004 | 21 | NIH | 1/25/2026 | $1 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | CoVPN 3008 2022-2023 | 000 | 21 | NIH | 1/23/2026 | $15,428,408 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 003 | 21 | NIH | 1/24/2026 | $1 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 002 | 21 | NIH | 1/23/2026 | $1 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 001 | 21 | NIH | 1/22/2026 | $1 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 000 | 21 | NIH | 1/14/2026 | $17,863,384 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 000 | 21 | NIH | 1/14/2026 | $250,000 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 000 | 21 | NIH | 1/14/2026 | $500,000 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 010 | 21 | NIH | 6/4/2026 | $0 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 010 | 21 | NIH | 6/4/2026 | $0 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 010 | 21 | NIH | 6/4/2026 | $0 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 009 | 21 | NIH | 6/3/2026 | $14,263,383 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 009 | 21 | NIH | 6/3/2026 | $250,000 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 006 | 21 | NIH | 1/27/2026 | $1 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 005 | 21 | NIH | 1/26/2026 | $1 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | CoVPN 3008 2022-2023 | 001 | 21 | NIH | 5/7/2026 | $15,421,147 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | P30CA015704 | Cancer Center Support Grant | 000 | 51 | NIH | 3/25/2026 | $70,000 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | P30CA015704 | Cancer Center Support Grant | 000 | 51 | NIH | 3/25/2026 | $11,169,523 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AG098480 | Immune aging and outcomes in adult survivors of childhood cancer | 001 | 1 | NIH | 4/22/2026 | $35,826 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AG098480 | Immune aging and outcomes in adult survivors of childhood cancer | 000 | 1 | NIH | 4/17/2026 | $762,675 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI179712 | Metabolite- and cytokine-mediated signals interact to control human CD8 T cell responses in tissues | 000 | 2 | NIH | 1/10/2026 | $849,176 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U01CA214057 | Developing CVD prediction models for women with early stage breast cancer | 001 | 6 | NIH | 4/16/2026 | $72,005 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U01CA214057 | Developing CVD prediction models for women with early stage breast cancer | 000 | 6 | NIH | 1/19/2026 | $648,055 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UG1CA287013 | Statistics and Data Management Center (SDMC) for the NCI Cancer Screening Research Network (CSRN) | 001 | 3 | NIH | 4/16/2026 | $149,661 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UG1CA287013 | Statistics and Data Management Center (SDMC) for the NCI Cancer Screening Research Network (CSRN) | 000 | 3 | NIH | 1/13/2026 | $1,346,937 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI175535 | Defining Protective CMV Immunity after Transplantation | 000 | 4 | NIH | 2/24/2026 | $774,089 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA297681 | Statistical Methods for Precision Prevention | 001 | 2 | NIH | 4/16/2026 | $50,561 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA297681 | Statistical Methods for Precision Prevention | 000 | 2 | NIH | 12/5/2025 | $455,052 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | F32HD113384 | Developmental mechanisms specifying vagal innervation of organ targets | 001 | 3 | NIH | 4/13/2026 | $1,356 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | F32HD113384 | Developmental mechanisms specifying vagal innervation of organ targets | 000 | 3 | NIH | 1/9/2026 | $80,224 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI179457 | Early intervention with anti-proliferative therapy close to ART initiation to limit long-term SIV persistence | 000 | 3 | NIH | 4/21/2026 | $828,228 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R13AI189265 | Flow Cytometry Workshops in Africa | 000 | 2 | NIH | 1/14/2026 | $69,132 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA295090 | MAPK-driven kinetochore stress in cancer | 000 | 2 | NIH | 4/1/2026 | $646,440 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UH3DA057032 | ACT on Vaping: Digital Therapeutic for Young Adult Vaping Cessation | 001 | 4 | NIH | 2/24/2026 | $812,783 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R35GM140823 | Mechanisms of transcriptional regulation and transcription factor specificity | 003 | 6 | NIH | 3/17/2026 | $1,105,868 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U19AI174242 | Self-amplifying mRNA-based vaccines to elicit VRC01-class bnAbs | 000 | 4 | NIH | 2/19/2026 | $1,583,952 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R35GM144128 | Data analysis tools for leveraging massive public data to improve hypothesis-driven research | 000 | 6 | NIH | 2/23/2026 | $431,963 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA287476 | Interrogating a novel axis of tumor suppression in small cell lung cancer | 001 | 2 | NIH | 4/16/2026 | $54,890 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA287476 | Interrogating a novel axis of tumor suppression in small cell lung cancer | 000 | 2 | NIH | 12/5/2025 | $494,025 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI177095 | Guiding the maturation of anti-CD4-BS bnAbs through sequential heterologous Env immunization | 000 | 3 | NIH | 1/30/2026 | $876,168 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R35GM148166 | Biophysical and structural studies of protein and enzyme mechanism, evolution, and engineering | 000 | 4 | NIH | 5/27/2026 | $616,000 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI069481 | Seattle Clinical Trials Unit | 002 | 21 | NIH | 6/9/2026 | $0 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI069481 | Seattle Clinical Trials Unit | 001 | 21 | NIH | 3/31/2026 | $764,777 |
|
